Clinical Trials Logo

Clinical Trial Summary

There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.


Clinical Trial Description

Eosinophilia is defined as an absolute eosinophil count exceeding 500 cells per microliter, calculated by multiplying the white blood cell count by the percentage of eosinophils. Cause of eosinophilia vary from mild to life-threatening disease. Prevalence of each cause of eosinophilia vary on study population, the most common etiology in developing country is parasite infection. Stool microscopy can be conducted using various methods. The Kato-Katz technique, recommended by the WHO, exhibits a sensitivity of only 52.4 percent (95%CI = 47.6 - 57.1 percent). More sensitive methods for parasite detection in stool, such as stool culture or PCR, are not readily available and can be costly. In the intervention group of this study, the investigators employed three different parasite detection methods (stool microscopy, stool culture, and PCR) to enhance sensitivity in detecting parasites. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06265870
Study type Interventional
Source Prince of Songkla University
Contact Thareerat Ananchaisarp
Phone +66858898592
Email thareerat.a@psu.ac.th
Status Not yet recruiting
Phase N/A
Start date April 10, 2024
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Withdrawn NCT03989635 - Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. Phase 2
Recruiting NCT03801434 - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Phase 2
Recruiting NCT04018118 - Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Enrolling by invitation NCT04252235 - Home Air Purification for Eosinophilic COPD N/A
Completed NCT03237221 - Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma
Recruiting NCT00091871 - A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Terminated NCT00230334 - Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Phase 2
Recruiting NCT04322422 - Clinical Characteristics and Treatment of Chest Tightness Variant Asthma N/A
Recruiting NCT04961060 - Drivers of Eosinophilic COPD Exacerbations
Completed NCT03450083 - Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis Phase 2
Recruiting NCT00939263 - Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index N/A
Terminated NCT04128371 - Mepolizumab in Episodic Angioedema With Eosinophilia Phase 2
Completed NCT01524536 - Steroid Treatment for Hypereosinophilic Syndrome Phase 4
Completed NCT02360696 - Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children
Recruiting NCT05942222 - A Randomized, Real-world Head-to-head Study of Dupilumab Versus Mepolizumab in Danish CRSwNP Patients Phase 4
Recruiting NCT00001406 - Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia